Table 1.
Demographic characteristics of patients from the pooled analysisa
| Clinical study (ID) | Sandoglobulin® NF liquid (NCT00168012) | Privigen® (NCT00168025) | Privigen® (NCT00322556) |
|---|---|---|---|
| Total number of patients | 42 | 80 | 55 |
| Indication, n (%) | |||
| CVID | 32 (76.2) | 59 (73.8) | 44 (80.0) |
| XLA | 10 (23.8) | 21 (26.3) | 11 (20.0) |
| Gender, n (%) | |||
| Female | 13 (31.0) | 34 (42.5) | 29 (52.7) |
| Male | 29 (69.0) | 46 (57.5) | 26 (47.3) |
| Age (years), mean (SD) | 32.2 (18.3) | 28.2 (19.3) | 29.9 (20.8) |
| BMI (kg/m2), mean (SD) | 22.5 (5.1) (n = 38) |
23.5 (6.3) (n = 80) |
24.5 (7.8) (n = 53) |
| Duration of PIDb (years), mean (SD) |
10.9 (8.8) | 8.6 (7.5) | 8.12 (6.8) |
| IgG trough level (g/L), mean (SD) |
9.95 (2.69) (n = 41) |
9.40 (2.75) (n = 79) |
9.72 (2.23) (n = 54) |
| Median weekly dose (mg/kg) | 125.5 | 117.8 | 128.2 |
BMI body mass index, CVID common variable immunodeficiency, PID primary immunodeficiency, SD standard deviation, XLA X-linked agammaglobulinemia
aData for well-being are available only for a subset of patients
bPrior to study entry